Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant Acinetobacter baumannii Strains

Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy in the past, and now Acinetobacters become resistant to nearly all antibiotics. Because of the resistance potential to colistin and the concer...

Full description

Saved in:
Bibliographic Details
Published inMicrobial drug resistance (Larchmont, N.Y.) Vol. 26; no. 5; p. 429
Main Authors Sertcelik, Ahmet, Baran, Irmak, Akinci, Esragul, Mumcuoglu, Ipek, Bodur, Hurrem
Format Journal Article
LanguageEnglish
Published United States 01.05.2020
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy in the past, and now Acinetobacters become resistant to nearly all antibiotics. Because of the resistance potential to colistin and the concerns about toxicity, especially for high doses, colistin combination therapies are preferred nowadays. In this study, we aimed to investigate whether combinations of colistin with meropenem, sulbactam, fosfomycin, vancomycin, and minocycline are synergic or not and to determine minocycline susceptibility rate, which is not in use in our country. For the studied 23 Acinetobacter strains, the highest synergy was between colistin and vancomycin, which was shown in 4 (17.4%) strains. The synergy of colistin with meropenem and fosfomycin was detected for 1 (4.3%) strain, the synergy of colistin with minocycline was detected for 2 (8.6%) strains, and no synergy was detected for colistin-sulbactam combination. All the strains were susceptible to minocycline. None of the antibiotic combinations was antagonistic. They had synergistic and additive interactions. Thus, these combinations can be used in clinical practices. The remarkable synergistic interaction of colistin-vancomycin combination and high susceptibility to minocycline highlight the need for more researches on these subjects.
AbstractList Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy in the past, and now Acinetobacters become resistant to nearly all antibiotics. Because of the resistance potential to colistin and the concerns about toxicity, especially for high doses, colistin combination therapies are preferred nowadays. In this study, we aimed to investigate whether combinations of colistin with meropenem, sulbactam, fosfomycin, vancomycin, and minocycline are synergic or not and to determine minocycline susceptibility rate, which is not in use in our country. For the studied 23 Acinetobacter strains, the highest synergy was between colistin and vancomycin, which was shown in 4 (17.4%) strains. The synergy of colistin with meropenem and fosfomycin was detected for 1 (4.3%) strain, the synergy of colistin with minocycline was detected for 2 (8.6%) strains, and no synergy was detected for colistin-sulbactam combination. All the strains were susceptible to minocycline. None of the antibiotic combinations was antagonistic. They had synergistic and additive interactions. Thus, these combinations can be used in clinical practices. The remarkable synergistic interaction of colistin-vancomycin combination and high susceptibility to minocycline highlight the need for more researches on these subjects.
Author Sertcelik, Ahmet
Bodur, Hurrem
Mumcuoglu, Ipek
Akinci, Esragul
Baran, Irmak
Author_xml – sequence: 1
  givenname: Ahmet
  surname: Sertcelik
  fullname: Sertcelik, Ahmet
  organization: Department of Infectious Diseases and Clinical Microbiology and Ankara Numune Training and Research Hospital, Ankara, Turkey
– sequence: 2
  givenname: Irmak
  surname: Baran
  fullname: Baran, Irmak
  organization: Department of Medical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey
– sequence: 3
  givenname: Esragul
  surname: Akinci
  fullname: Akinci, Esragul
  organization: Department of Infectious Diseases and Clinical Microbiology and Ankara Numune Training and Research Hospital, Ankara, Turkey
– sequence: 4
  givenname: Ipek
  surname: Mumcuoglu
  fullname: Mumcuoglu, Ipek
  organization: Department of Medical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey
– sequence: 5
  givenname: Hurrem
  surname: Bodur
  fullname: Bodur, Hurrem
  organization: Department of Infectious Diseases and Clinical Microbiology and Ankara Numune Training and Research Hospital, Ankara, Turkey
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31657659$$D View this record in MEDLINE/PubMed
BookMark eNo1UMtOwzAQtBCIlseRK_IHNMWusZMcq0IBqRUSBa7Iz7IosSvbAfUb-SlSCqedfc3szgk69MFbhC4oGVNS1VetieMJofWYkKo6QENaM1pU19fVAJ2k9EEI4VSwYzRgVPBS8HqIvldbb-MaUgaNpzrDJ2SwCQeHZ6HZlX0PWgVeZgg-4S_I73hpY9hYb9sRXnWNkjrLHi7BB73VDXg7wjeQgoGuxfOQXGi3GvwIh4hfpdf7FE_XEnzK_ahzNlqf8azpH9qLy6jkr0TxZFN_h-zb037L5rDTsxEr2bXSewC8ynHHdIaOnGySPf-Lp-hlfvs8uy8Wj3cPs-mi0EzwXNQ158pYoUVZaycUd9qRUvJSVk4xIYSuKDXEsd45xww3tNTGsNJWZMKMMpNTdLnn3XSqteZtE6GVcfv27-rkBwocf-E
CitedBy_id crossref_primary_10_1128_spectrum_01199_23
crossref_primary_10_3390_pharmaceutics12060501
crossref_primary_10_1080_14740338_2024_2416256
crossref_primary_10_3390_antibiotics10060646
crossref_primary_10_1007_s42770_023_01153_5
crossref_primary_10_3390_antibiotics9030119
crossref_primary_10_1016_j_ijmmb_2022_06_009
crossref_primary_10_1016_j_ijmmb_2021_04_006
crossref_primary_10_1021_acsinfecdis_0c00001
crossref_primary_10_3390_pharmaceutics13020162
crossref_primary_10_1016_j_jiph_2021_09_015
crossref_primary_10_1080_14786419_2020_1808635
crossref_primary_10_1038_s42003_020_01511_1
crossref_primary_10_1016_j_ijantimicag_2020_106271
crossref_primary_10_1128_spectrum_01928_22
crossref_primary_10_1007_s12088_022_01045_6
crossref_primary_10_1016_j_ijantimicag_2023_106880
crossref_primary_10_1248_bpb_b23_00642
crossref_primary_10_3390_antibiotics9080500
crossref_primary_10_1016_j_micpath_2023_106233
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1089/mdr.2019.0088
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1931-8448
ExternalDocumentID 31657659
Genre Journal Article
GroupedDBID ---
.GJ
0R~
123
29M
34G
39C
4.4
53G
7X7
88E
88I
8C1
8FE
8FH
8FI
8FJ
AAHBH
ABBKN
ABUWG
ACGFS
ACGOD
ACIWK
ACPRK
ADBBV
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BBNVY
BENPR
BHPHI
BNQNF
BPHCQ
BVXVI
CAG
CCPQU
CGR
COF
CS3
CUY
CVF
DU5
DWQXO
EBS
ECM
EIF
EJD
F5P
FYUFA
GNUQQ
HCIFZ
HMCUK
IAO
IER
IHR
IM4
INH
INR
ITC
LK8
M1P
M2P
M7P
MV1
NPM
NQHIM
O9-
P2P
PHGZT
PQQKQ
PROAC
PSQYO
RIG
RML
RMSOB
UE5
UKHRP
ID FETCH-LOGICAL-c365t-9955bde6c679cf6b5fcf07a57a8fb3666c811d0f3844f3d5d17cdd37e8023dbd2
IngestDate Thu Apr 03 06:58:32 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords checkerboard
synergy
minocycline
colistin
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c365t-9955bde6c679cf6b5fcf07a57a8fb3666c811d0f3844f3d5d17cdd37e8023dbd2
PMID 31657659
ParticipantIDs pubmed_primary_31657659
PublicationCentury 2000
PublicationDate 2020-May
PublicationDateYYYYMMDD 2020-05-01
PublicationDate_xml – month: 05
  year: 2020
  text: 2020-May
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Microbial drug resistance (Larchmont, N.Y.)
PublicationTitleAlternate Microb Drug Resist
PublicationYear 2020
SSID ssj0005163
Score 2.361498
Snippet Colistin became the primary treatment option for Acinetobacters that had developed a high rate of resistance to carbapenems which were the first-line therapy...
SourceID pubmed
SourceType Index Database
StartPage 429
SubjectTerms Acinetobacter baumannii - drug effects
Anti-Bacterial Agents - pharmacology
Bacteriological Techniques
Carbapenems - pharmacology
Colistin - pharmacology
Drug Combinations
Drug Resistance, Bacterial - drug effects
Drug Synergism
Fosfomycin - pharmacology
Humans
Meropenem - pharmacology
Minocycline - pharmacology
Sulbactam - pharmacology
Vancomycin - pharmacology
Title Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant Acinetobacter baumannii Strains
URI https://www.ncbi.nlm.nih.gov/pubmed/31657659
Volume 26
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3JbtswEIaJpEWDXLq4-wYeilwkpZK1H1WjQVrURdA6RW4BRVKuUMsyZPngvmJfqjOkNqcpulwEQ7QkwvOZmiFnfhLyCoI1FoTMtgTEP5bnMWml3IcoBdgAb9bOvAynBqYfg9Nz7_2Ff7G3f2eQtbSp02P-_dq6kv-xKpwDu2KV7D9YtrspnIDPYF84goXh-Fc2_rzFyj0ltWwkXO0DkWsR2Um5wNNY0VdA7Nvku6lJ16nE-felLHRSziJlvNZUTPNlybdca49OlDCnyDeFcVKCa1tsuZYbKCvjC6CiTxjJnOXgYcKX9UYrtTFZoPy_rvuqUqYeZX2Sa3RUoTnBlXwcRVAl2kgZLiIs8xyXx_FOQ2d5miuVKFxGqjZzo2ruwZVb_AH_ofBL1zv1YlmbvFxzucjVSJ98Lfoi7zes0jO-7-CF1BUpJd9wxUG9FtYVmw9zJQu-KeeLjbpk1QgbN5MkY7tPSTyWemCPXceKPK3q2Y78ula_IdwfDOOe7vEvrxc7QnXWQqCQrINCp3pLwgFqq0Kx5joBBHJ-_OfWK2rfbdM-2Ye4BzdyxdmnNmUJnOdGJxZ68nqnH4fkoL32SoSkPKXZXXK7CXFoonm9R_bkckRu6U1PtyNyMG3SOUbk6EwLp29NOuvrANcmPaJnvaT69j75MSCd9qTTMqMt6XRIOkXSaUe6STvOTTqg3KQt47Rn3KRlRXvCaUM47QinmnD18GsIpzuE045w2hD-gJyfvJ1NTq1mGxKLu4FfW3Hs-6mQAQ_CmGdB6mc8s0PmhyzKUhfCfx45jrAzF_DKXOELJ-RCuKFEbUWRivFDcmMJ_XpMqOtz2-bjNApC6UWSRTHzWCSiUDDMF02fkEfacpcrrTVz2dr06W9bnpHDnvjn5GYGg5t8AZ5ynb5U-PwEAQnI9A
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synergistic+Activities+of+Colistin+Combinations+with+Meropenem%2C+Sulbactam%2C+Minocycline%2C+Disodium+Fosfomycin%2C+or+Vancomycin+Against+Different+Clones+of+Carbapenem-Resistant+Acinetobacter+baumannii+Strains&rft.jtitle=Microbial+drug+resistance+%28Larchmont%2C+N.Y.%29&rft.au=Sertcelik%2C+Ahmet&rft.au=Baran%2C+Irmak&rft.au=Akinci%2C+Esragul&rft.au=Mumcuoglu%2C+Ipek&rft.date=2020-05-01&rft.eissn=1931-8448&rft.volume=26&rft.issue=5&rft.spage=429&rft_id=info:doi/10.1089%2Fmdr.2019.0088&rft_id=info%3Apmid%2F31657659&rft_id=info%3Apmid%2F31657659&rft.externalDocID=31657659